Groupama Asset Managment Purchases 2,483,697 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Groupama Asset Managment lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 160.4% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 4,032,082 shares of the biopharmaceutical company’s stock after purchasing an additional 2,483,697 shares during the period. Groupama Asset Managment owned about 3.05% of Alnylam Pharmaceuticals worth $18,610,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its stake in Alnylam Pharmaceuticals by 2.0% in the third quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after buying an additional 268,313 shares during the last quarter. Capital Research Global Investors boosted its holdings in shares of Alnylam Pharmaceuticals by 0.4% in the 3rd quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock valued at $3,293,516,000 after acquiring an additional 31,184 shares during the last quarter. Orbis Allan Gray Ltd boosted its holdings in Alnylam Pharmaceuticals by 29.8% in the second quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock valued at $691,771,000 after purchasing an additional 486,489 shares during the last quarter. Norges Bank purchased a new stake in Alnylam Pharmaceuticals in the second quarter valued at $662,837,000. Finally, American Century Companies Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 1.9% in the second quarter. American Century Companies Inc. now owns 1,793,846 shares of the biopharmaceutical company’s stock worth $584,957,000 after buying an additional 33,411 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 9,577 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the completion of the sale, the chief executive officer owned 78,411 shares in the company, valued at $28,452,215.46. This represents a 10.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total transaction of $848,055.70. Following the completion of the transaction, the executive vice president owned 21,264 shares in the company, valued at approximately $7,874,697.12. This represents a 9.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 53,923 shares of company stock worth $18,072,087. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Trading Down 1.8%

NASDAQ ALNY opened at $314.80 on Thursday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The firm has a 50 day moving average of $338.90 and a two-hundred day moving average of $406.96. The company has a quick ratio of 2.71, a current ratio of 2.76 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $41.75 billion, a PE ratio of 184.09 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). The business had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business’s quarterly revenue was up 84.9% compared to the same quarter last year. During the same period last year, the company earned ($0.65) EPS. As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Canaccord Genuity Group increased their target price on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Chardan Capital reduced their price objective on Alnylam Pharmaceuticals from $475.00 to $425.00 and set a “buy” rating for the company in a research note on Friday, February 13th. Leerink Partners decreased their target price on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research note on Monday, December 15th. Needham & Company LLC lowered their target price on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a report on Thursday, February 12th. Finally, Truist Financial cut their target price on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating for the company in a research note on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $468.84.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.